New combo drug tested to fight spreading breast cancer
NCT ID NCT01658462
Summary
This study tested whether adding a drug called nintedanib to standard chemotherapy (docetaxel) could help control advanced breast cancer for longer. It involved 51 adults with HER2-negative breast cancer that had returned or spread, who were starting their first or second round of chemotherapy. The main goal was to see if the combination delayed cancer growth compared to chemotherapy alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CH Compiègne-Noyon
Compiègne, 60200, France
-
CHU Amiens- Hôpital Sud
Amiens, 80 054, France
-
CMCO de la Côte d'Opale
Saint-Martin-Boulogne, 62280, France
-
Centre Alexis Vautrin
Vandœuvre-lès-Nancy, 54 500, France
-
Centre Léonard de Vinci
Dechy, 59 187, France
-
Centre Oscar Lambret
Lille, 59 020, France
-
Centre Pierre Curie
Beuvry, 62660, France
-
Hôpital Bretonneau
Tours, 37044, France
-
Hôpital Privé les Bonnettes
Arras, 62000, France
-
Institut Jean Godinot
Reims, 51056, France
-
Nouvelle Clinique des Dentellières
Valenciennes, 59300, France
-
Polyclinique de Limoges - site Chénieux
Limoges, 87039, France
Conditions
Explore the condition pages connected to this study.